Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1/2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Head & Neck 1

Conditions

Lung Neoplasms 3Carcinoma, Non-Small-Cell Lung 2Squamous Cell Carcinoma of Head and Neck 1Pulmonary Disease, Chronic Obstructive 1Pneumonia 1Colonic Neoplasms 1

Interventions

pembrolizumab 244Carboplatin 213Pemetrexed 179Cisplatin 133Paclitaxel 115Nivolumab 102Docetaxel 88osimertinib 84durvalumab 79Specimen Handling 56atezolizumab 55Gemcitabine 53Drug Therapy 53Magnetic Resonance Spectroscopy 50Radiosurgery 49Radiotherapy 48Ipilimumab 41130-nm albumin-bound paclitaxel 39cemiplimab 38Bevacizumab 35tislelizumab 31Cetuximab 30amivantamab 23Taxes 22Blood Specimen Collection 21Platinum Compounds 20Immunotherapy 18Immune Checkpoint Inhibitors 18Radiation 17Erlotinib Hydrochloride 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma, Non-Small-Cell Lung × CIMAvax EGF × 1 year × Clear all
NCT04298606 2026-03-17

A Vaccine (CIMAvax-EGF) for the Prevention of Lung Cancer Development or Recurrence

Roswell Park Cancer Institute

Phase EARLY_PHASE1 Completed
20 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pneumonia, Pulmonary Disease, Chronic Obstructive

NCT02955290 2025-11-10

CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer

Roswell Park Cancer Institute

Phase 1/2 Active not recruiting
51 enrolled
Head & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡